MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study
Open Access
- 30 December 2021
- journal article
- research article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 12 (5) , 2609-2618
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- The c-MET/PI3K Signaling Is Associated with Cancer Resistance to Doxorubicin and Photodynamic Therapy by Elevating BCRP/ABCG2 ExpressionMolecular Pharmacology, 2015
- High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancerLung Cancer, 2014
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- ABC Transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) Expression in the Developing Human CNSNeuropediatrics, 2008
- Side Population in Human Lung Cancer Cell Lines and Tumors Is Enriched with Stem-like Cancer CellsCancer Research, 2007
- The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate bindingProtein Science, 2006
- Breast Cancer Resistance Protein in Drug Resistance of Primitive CD34+38− Cells in Acute Myeloid LeukemiaClinical Cancer Research, 2005
- Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognitionBiochimica et Biophysica Acta (BBA) - Biomembranes, 2005
- Reversing Effect of Agosterol A, a Spongean Sterol Acetate, on Multidrug Resistance in Human Carcinoma CellsJapanese Journal of Cancer Research, 2001
- Multidrug resistance (MDR) in cancerEuropean Journal of Pharmaceutical Sciences, 2000